Schering Aktiengesellschaft

Schering Aktiengeseellschaft

David N Stephens

Andreas Huth

Dieter Seidelmann

Ralph Schmiechen

Dieter Rahtz

Herbert H Schneider

Helmut Biere

Lechoslaw Turski

Mogens Engelstoft

John Bondo Hansen

Martin Kruger

Ralph Rohde

Peter Holscher

Peter A Loschmann

Ingrid Schumann

Ilse Beetz

Karin G Steppuhn

Rudolf Wiechert

Helmut Wachtel

Leif H Jensen

Erling N Petersen

Frank Waetjen

John S Andrews

Preben Olsen

Thomas Klockgether

Martin Gieseler

Peter-Andreas L&ouml;schmann

Karin Bressler

The disclosure relates to quinoxaline derivates of Formula I

Quinoxaline-carboxylic acid derivatives

The new use of antagonists of the AMPA receptor complex and its physiologically compatible salts as pharmaceutical agents for prevention and treatment of Parkinson's disease as well as pharmaceutical agents, which contain these compounds, is described.

Use of quisqualate receptor antagonists

The disclosure relates to quinoxaline derivatives of Formula I ##STR1## wherein R.sup.1, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined in the disclosure, as well as their production and use in medicinal agents.

Quinoxaline-phosphonic acid derivatives

Hetaryloxy-.beta.-carbolines of formula I ##STR1## in which R.sup.A means a triazine or benzocondensed hetaryl radical with 1-2 nitrogen atoms optionally substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 or a 5- or 6-membered hetaryl radical with 1-2 nitrogen atoms substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 are useful pharmaceutical agents.

Hetaryloxy-.beta.-carbolines, their production and use in pharmaceutical

Pharmaceutical agents for preventing the development of tolerance during

The use of the non-NMDA receptor antagonists quisqualate or kainate antagonists or their physiologically compatible salts for treatment of withdrawal symptoms after drug abuse as well as the combination of the new pharmaceutical agents with NMDA antagonists are described.

Pharmaceutical agent for treatment of withdrawal symptoms

Hetaryloxy-.beta.-carbolines of formula I ##STR1## in which R.sup.A means a benzocondensed hetaryl radical with 1-2 nitrogen atoms optionally substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 or a 5- or 6-membered hetaryl radical with 1-2 nitrogen atoms substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 are useful pharmaceutical agents.

Hetaryloxy-.beta.-carbolines, and use as pharmaceutical agents for

N-hetaryl imidazole derivatives of general Formula I ##STR1## are disclosed in which

N-hetaryl imidazole derivatives

Heteroaryloxy-.beta.-carboline derivatives of general Formula I ##STR1## wherein R.sup.1 is an optionally substituted heteroaryl residue,

Heteroaryloxy-.beta.-carboline derivatives, their preparation and their

Imidazole derivatives

Phenoxy-substituted beta-carbolines of the formula I ##STR1## X is COOR.sup.3, CONHC.sub.1-3 -alkyl or oxadiazolyl of the formula ##STR2## R.sup.2 is H, lower alkyl or cycloalkyl, R.sup.3 is lower alkyl,

Phenoxy-substituted beta-carboline derivatives, their production and

.beta.-Carbolines of general Formula I ##STR1## wherein Y represents the residue ##STR2## and R.sup.a and R.sup.b, being identical or different, mean respectively hydrogen, C.sub.1-6 -alkoxy, phenyl, C.sub.3-7 -cyclo-alkyl, optionally substituted C.sub.1-6 -alkyl or C.sub.1-6 -alkoxycarbonyl, and R.sup.c and R.sup.d, being identical or different, mean respectively hydrogen or C.sub.1-6 -alkyl or jointly a linkage, and

Isoxazole-.beta.-carboline derivatives

Heteroaryloxy-beta-carboline derivatives, their preparation and their

5,6,7,8-tetrahydro-beta-carbolines derivatives of formula I ##STR1## wherein R.sup.1 is an oxadiazolyl radical of the formula ##STR2## COOR.sup.3 or CONR.sup.4 R.sup.5, R.sup.2 is H, lower alkyl or cycloalkyl,

Tetrahydro-beta-carbolines, and their use as drugs

Compounds of formula I ##STR1## wherein X is COOR.sup.3 or an oxadiazolyl radical of the formula or

Growing community of inventors

Berlin, Germany

David N Stephens